|
|
 |
 |
|
|
 |
| |
Financial Highlights 2006
Boehringer Ingelheim group of companies |
|
| |
|
2006 |
|
2005 |
|
Change |
|
Amounts in millions of EUR,
unless otherwise indicated
|
|
|
|
|
|
|
|
| Net sales |
|
10,574 |
|
9,535 |
|
11% |
|
| |
|
|
|
|
|
|
|
| Net sales by region |
|
|
|
|
|
|
|
| Europe |
|
31% |
|
33% |
|
|
|
| Americas |
|
51% |
|
48% |
|
|
|
| Asia, Australasia, Africa |
|
18% |
|
19% |
|
|
|
| |
|
|
|
|
|
|
|
| Net sales by business area |
|
|
|
|
|
|
|
| Human Pharmaceuticals |
|
96% |
|
96% |
|
|
|
| Animal Health |
|
4% |
|
4% |
|
|
|
|
|
|
|
|
|
|
|
| Research and Development |
|
1,574 |
|
1,360 |
|
16% |
|
| Personnel costs |
|
2,836 |
|
2,671 |
|
6% |
|
| Average number of employees* |
|
38,428 |
|
37,406 |
|
3% |
|
| |
|
|
|
|
|
|
|
| Operating income |
|
2,140 |
|
1,923 |
|
11% |
|
| Operating income as % of sales |
|
20.2% |
|
20.2% |
|
|
|
| |
|
|
|
|
|
|
|
| Income after taxes |
|
1,729 |
|
1,514 |
|
14% |
|
| Income after taxes as % of sales |
|
16.4% |
|
15.9% |
|
|
|
| |
|
|
|
|
|
|
|
| Shareholders' equity |
|
5,175 |
|
4,609 |
|
12% |
|
| Return on shareholders' equity |
|
37.4 |
|
34.2% |
|
|
|
| |
|
|
|
|
|
|
|
| Cash Flow |
|
2,317 |
|
2,069 |
|
12% |
|
| |
|
|
|
|
|
|
|
| Investments in tangible assets |
|
596 |
|
532 |
|
12% |
|
| Depreciation of tangible assets |
|
419 |
|
439 |
|
-5% |
|
*including the total number of employees in joint ventures
included in the consolidation |
|
|
|
|
 
|
|
|
|
